Fluoroquinolone Therapy for the Prevention of Multidrug-Resistant Tuberculosis in Contacts. A Cost-Effectiveness Analysis.
BACKGROUND
Fluoroquinolone (FQN) therapy of latent tuberculosis infection among contacts of individuals with multidrug-resistant tuberculosis (MDR-TB) is controversial.


OBJECTIVE
To determine the potential benefits, risks (including acquired FQN resistance), and cost-effectiveness of FQN therapy to prevent TB in contacts of individuals with MDR-TB.


METHODS
We used decision analysis to estimate costs and outcomes associated with no therapy compared with a 6-month course of daily FQN therapy to treat latent TB infection in contacts of individuals with MDR-TB. Outcomes modeled were the incidence of MDR-TB, MDR-TB with FQN resistance, TB-related death, quality-adjusted life years, and health system costs.


RESULTS
FQN preventive therapy resulted in health system savings, lower incidence of MDR-TB, and lower mortality than no treatment. We found the incidence of MDR-TB with acquired FQN resistance would also be lower with FQN therapy of infected contacts.


CONCLUSIONS
In our model, FQN preventive therapy resulted in substantial health system savings and in reduced mortality, incidence of MDR-TB, and incidence of acquired FQN-resistant disease as well as improved quality of life. FQN therapy remained cost saving with improved outcomes even if the effectiveness of therapy in preventing MDR-TB was as low as 10%.
1 Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill University, Montreal, Quebec, Canada; and.|2 McGill International TB Centre, Montreal, Quebec, Canada.
Gregory J
GJ
Fox
1 Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill University, Montreal, Quebec, Canada; and.|2 McGill International TB Centre, Montreal, Quebec, Canada.
Olivia
O
Oxlade
1 Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill University, Montreal, Quebec, Canada; and.|2 McGill International TB Centre, Montreal, Quebec, Canada.
Dick
D
Menzies
D000328:Adult; D000900:Anti-Bacterial Agents / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis / Q000706:statistics & numerical data*; D005260:Female; D024841:Fluoroquinolones / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D018803:Models, Economic; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones
antitubercular agents; cost-effectiveness analysis; latent tuberculosis infection; multidrug-resistant tuberculosis